Brain and Behavior. 2018;8:e00955.
1 of 8
1 | INTRODUCTION
Multiple sclerosis (MS) is the most common immune- mediated,
chronic, inflammatory disease of the central nervous system, typ-
ically affecting the white matter (WM) in the form of multifocal
areas of demyelination, as historically known. Nevertheless, in
recent years, several neuropathological and imaging studies have
demonstrated also the involvement of the cortical and deep gray
matter (GM), in the form of an inflammatory process, both focal
and diffuse, in addition to a neurodegenerative one leading to
Correlation between cortical lesions and cognitive impairment
in multiple sclerosis
| Stefania Graziuso
| Elena Tsantes
| Girolamo Crisi
| Franco Granella
provided the original work is properly cited.
©2018TheAuthors. Brain and Behavior published by Wiley Periodicals, Inc.
Neurosciences Unit, Department of
Medicine and Surgery (DMEC), University of
Parma, Parma, Italy
Neuroradiology Unit, Department of
Diagnostic, Parma University Hospital,
Erica Curti, Neurosciences Unit, Department
of Medicine and Surgery (DMEC), University
of Parma, Parma, Italy.
Objectives: Gray matter (GM) damage is well known as a fundamental aspect of mul-
double inversion recovery (DIR) sequences, has been demonstrated to correlate with
cognitiveimpairment (CI).The aim ofthis study was toinvestigatethe role ofCLs
number in predicting CI in a cohort of patients with MS in a clinical practice setting.
Materials and methods:ThirtyconsecutivepatientswithMSpresentingCLs(CL+)at
high- field (3.0 T) MRI 3D- DIR sequences and an even group of MS patients without
CLs(CL-)asacontrol, wereinvestigated withthe RaoBriefRepeatable Battery of
Results: Among the sixty patients with MS enrolled, forty-seven (78.3%) had a
greater proportion of progressive forms (p = .03). The most affected region was the
Multivariate (logistic regression) analysis revealed a significant correlation between
logicscore in at least one BRB test(p = .04); it was also correlated with deficit at
PASAT3(p = .05) and Stroop Test (p = .02).
available in clinical practice, as a predictive factor of CI in patients with MS, in order
to improve the diagnosis and management of CI and monitor potential neuroprotec-
tive effects of therapies.
cognitive impairment, cortical lesions, double inversion recovery, multiple sclerosis